ATACAND Rx

Select the drug indication to add to your list

ATACAND

CHF and arrhythmias
Hypertension
Only 4 drugs may be compared at once

Generic Name and Formulations:

Candesartan cilexetil 4mg, 8mg, 16mg, 32mg; scored tabs.

Select therapeutic use:

Indications for ATACAND:

Heart failure (NYHA class II-IV and ejection fraction ≤40%), to reduce risk of death and hospitalization; alone or with an ACE inhibitor.

Adult:

≥18yrs: Initially 4mg once daily; double daily dose at 2-week intervals as tolerated to target 32mg once daily. Salt/volume depleted or moderate hepatic impairment: consider lower initial dose.

Children:

<18yrs: not recommended.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting or monitor closely. Monitor BP, renal function, serum K+ periodically. Hepatic or renal impairment. Severe CHF. Renal artery stenosis. Surgery. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:

See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes. Avoid aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors. Monitor lithium levels.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Headache, dizziness, hypotension, renal dysfunction, hyperkalemia, back pain, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare).

How Supplied:

Tabs 4mg, 8mg—30; 16mg, 32mg—30, 90

ATACAND 32mg tablets (Qty:30)

appx. price $142.00

Indications for ATACAND:

Hypertension.

Adult:

Individualize. ≥18yrs: Monotherapy and not volume-depleted: initially 16mg once daily; usual range: 8–32mg per day once daily or in 2 divided doses. Moderate hepatic impairment: initially 8mg once daily. Salt/volume depleted: consider lower initial dose. May add diuretic if needed.

Children:

<1yr or CrCl<30mL/min: not recommended. Give once daily or in 2 divided doses. 1–<6yrs (may give oral susp if unable to swallow tabs): initially 0.2mg/kg/day; usual range: 0.05–0.4mg/kg/day. 6–<17yrs (<50kg): initially 4–8mg/day; usual range: 2–16mg/day; (>50kg): initially 8–16mg/day; usual range: 4–32mg/day. Salt/volume depleted: consider lower initial dose.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting or monitor closely. Monitor BP, renal function, serum K+ periodically. Hepatic or renal impairment. Severe CHF. Renal artery stenosis. Surgery. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:

See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes. Avoid aliskiren in renal impairment (CrCl <60mL/min). Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors. Monitor lithium levels.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Headache, dizziness, hypotension, renal dysfunction, hyperkalemia, back pain, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare).

How Supplied:

Tabs 4mg, 8mg—30; 16mg, 32mg—30, 90

ATACAND 32mg tablets (Qty:30)

appx. price $142.00